Gene "Gene synonym" Ensembl "Gene description" Uniprot Chromosome Position "Protein class" "Biological process" "Molecular function" "Disease involvement" Evidence "HPA evidence" "UniProt evidence" "NeXtProt evidence" "MS evidence" "RNA tissue specificity" "RNA tissue distribution" "RNA tissue specificity score" "RNA tissue specific NX" "RNA cell line specificity" "RNA cell line distribution" "RNA cell line specificity score" "RNA cell line specific NX" "RNA cancer specificity" "RNA cancer distribution" "RNA cancer specificity score" "RNA cancer specific FPKM" "RNA brain regional specificity" "RNA brain regional distribution" "RNA brain regional specificity score" "RNA brain regional specific NX" "RNA blood cell specificity" "RNA blood cell distribution" "RNA blood cell specificity score" "RNA blood cell specific NX" "RNA blood lineage specificity" "RNA blood lineage distribution" "RNA blood lineage specificity score" "RNA blood lineage specific NX" "RNA mouse brain regional specificity" "RNA mouse brain regional distribution" "RNA mouse brain regional specificity score" "RNA mouse brain regional specific pTPM" "RNA pig brain regional specificity" "RNA pig brain regional distribution" "RNA pig brain regional specificity score" "RNA pig brain regional specific pTPM" Antibody "Reliability (IH)" "Reliability (Mouse Brain)" "Reliability (IF)" "Subcellular location" "Secretome location" "Blood concentration - Conc. blood IM [pg/L]" "Blood concentration - Conc. blood MS [pg/L]" "Subcellular main location" "Subcellular additional location" "Antibody RRID" "Pathology prognostics - Breast cancer" "Pathology prognostics - Cervical cancer" "Pathology prognostics - Colorectal cancer" "Pathology prognostics - Endometrial cancer" "Pathology prognostics - Glioma" "Pathology prognostics - Head and neck cancer" "Pathology prognostics - Liver cancer" "Pathology prognostics - Lung cancer" "Pathology prognostics - Melanoma" "Pathology prognostics - Ovarian cancer" "Pathology prognostics - Pancreatic cancer" "Pathology prognostics - Prostate cancer" "Pathology prognostics - Renal cancer" "Pathology prognostics - Stomach cancer" "Pathology prognostics - Testis cancer" "Pathology prognostics - Thyroid cancer" "Pathology prognostics - Urothelial cancer" "Tissue RNA - adipose tissue [NX]" "Tissue RNA - adrenal gland [NX]" "Tissue RNA - amygdala [NX]" "Tissue RNA - appendix [NX]" "Tissue RNA - basal ganglia [NX]" "Tissue RNA - bone marrow [NX]" "Tissue RNA - breast [NX]" "Tissue RNA - cerebellum [NX]" "Tissue RNA - cerebral cortex [NX]" "Tissue RNA - cervix, uterine [NX]" "Tissue RNA - colon [NX]" "Tissue RNA - corpus callosum [NX]" "Tissue RNA - ductus deferens [NX]" "Tissue RNA - duodenum [NX]" "Tissue RNA - endometrium 1 [NX]" "Tissue RNA - epididymis [NX]" "Tissue RNA - esophagus [NX]" "Tissue RNA - fallopian tube [NX]" "Tissue RNA - gallbladder [NX]" "Tissue RNA - heart muscle [NX]" "Tissue RNA - hippocampal formation [NX]" "Tissue RNA - hypothalamus [NX]" "Tissue RNA - kidney [NX]" "Tissue RNA - liver [NX]" "Tissue RNA - lung [NX]" "Tissue RNA - lymph node [NX]" "Tissue RNA - midbrain [NX]" "Tissue RNA - olfactory region [NX]" "Tissue RNA - ovary [NX]" "Tissue RNA - pancreas [NX]" "Tissue RNA - parathyroid gland [NX]" "Tissue RNA - pituitary gland [NX]" "Tissue RNA - placenta [NX]" "Tissue RNA - pons and medulla [NX]" "Tissue RNA - prostate [NX]" "Tissue RNA - rectum [NX]" "Tissue RNA - retina [NX]" "Tissue RNA - salivary gland [NX]" "Tissue RNA - seminal vesicle [NX]" "Tissue RNA - skeletal muscle [NX]" "Tissue RNA - skin 1 [NX]" "Tissue RNA - small intestine [NX]" "Tissue RNA - smooth muscle [NX]" "Tissue RNA - spinal cord [NX]" "Tissue RNA - spleen [NX]" "Tissue RNA - stomach 1 [NX]" "Tissue RNA - testis [NX]" "Tissue RNA - thalamus [NX]" "Tissue RNA - thymus [NX]" "Tissue RNA - thyroid gland [NX]" "Tissue RNA - tongue [NX]" "Tissue RNA - tonsil [NX]" "Tissue RNA - urinary bladder [NX]" "Tissue RNA - vagina [NX]" "Tissue RNA - B-cells [NX]" "Tissue RNA - dendritic cells [NX]" "Tissue RNA - granulocytes [NX]" "Tissue RNA - monocytes [NX]" "Tissue RNA - NK-cells [NX]" "Tissue RNA - T-cells [NX]" "Tissue RNA - total PBMC [NX]" "Cell RNA - A-431 [NX]" "Cell RNA - A549 [NX]" "Cell RNA - AF22 [NX]" "Cell RNA - AN3-CA [NX]" "Cell RNA - ASC diff [NX]" "Cell RNA - ASC TERT1 [NX]" "Cell RNA - BEWO [NX]" "Cell RNA - BJ [NX]" "Cell RNA - BJ hTERT+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [NX]" "Cell RNA - CACO-2 [NX]" "Cell RNA - CAPAN-2 [NX]" "Cell RNA - Daudi [NX]" "Cell RNA - EFO-21 [NX]" "Cell RNA - fHDF/TERT166 [NX]" "Cell RNA - HaCaT [NX]" "Cell RNA - HAP1 [NX]" "Cell RNA - HBEC3-KT [NX]" "Cell RNA - HBF TERT88 [NX]" "Cell RNA - HDLM-2 [NX]" "Cell RNA - HEK 293 [NX]" "Cell RNA - HEL [NX]" "Cell RNA - HeLa [NX]" "Cell RNA - Hep G2 [NX]" "Cell RNA - HHSteC [NX]" "Cell RNA - HL-60 [NX]" "Cell RNA - HMC-1 [NX]" "Cell RNA - HSkMC [NX]" "Cell RNA - hTCEpi [NX]" "Cell RNA - hTEC/SVTERT24-B [NX]" "Cell RNA - hTERT-HME1 [NX]" "Cell RNA - HUVEC TERT2 [NX]" "Cell RNA - K-562 [NX]" "Cell RNA - Karpas-707 [NX]" "Cell RNA - LHCN-M2 [NX]" "Cell RNA - MCF7 [NX]" "Cell RNA - MOLT-4 [NX]" "Cell RNA - NB-4 [NX]" "Cell RNA - NTERA-2 [NX]" "Cell RNA - PC-3 [NX]" "Cell RNA - REH [NX]" "Cell RNA - RH-30 [NX]" "Cell RNA - RPMI-8226 [NX]" "Cell RNA - RPTEC TERT1 [NX]" "Cell RNA - RT4 [NX]" "Cell RNA - SCLC-21H [NX]" "Cell RNA - SH-SY5Y [NX]" "Cell RNA - SiHa [NX]" "Cell RNA - SK-BR-3 [NX]" "Cell RNA - SK-MEL-30 [NX]" "Cell RNA - T-47d [NX]" "Cell RNA - THP-1 [NX]" "Cell RNA - TIME [NX]" "Cell RNA - U-138 MG [NX]" "Cell RNA - U-2 OS [NX]" "Cell RNA - U-2197 [NX]" "Cell RNA - U-251 MG [NX]" "Cell RNA - U-266/70 [NX]" "Cell RNA - U-266/84 [NX]" "Cell RNA - U-698 [NX]" "Cell RNA - U-87 MG [NX]" "Cell RNA - U-937 [NX]" "Cell RNA - WM-115 [NX]" "Blood RNA - basophil [NX]" "Blood RNA - classical monocyte [NX]" "Blood RNA - eosinophil [NX]" "Blood RNA - gdT-cell [NX]" "Blood RNA - intermediate monocyte [NX]" "Blood RNA - MAIT T-cell [NX]" "Blood RNA - memory B-cell [NX]" "Blood RNA - memory CD4 T-cell [NX]" "Blood RNA - memory CD8 T-cell [NX]" "Blood RNA - myeloid DC [NX]" "Blood RNA - naive B-cell [NX]" "Blood RNA - naive CD4 T-cell [NX]" "Blood RNA - naive CD8 T-cell [NX]" "Blood RNA - neutrophil [NX]" "Blood RNA - NK-cell [NX]" "Blood RNA - non-classical monocyte [NX]" "Blood RNA - plasmacytoid DC [NX]" "Blood RNA - T-reg [NX]" "Blood RNA - total PBMC [NX]" "Brain RNA - amygdala [NX]" "Brain RNA - basal ganglia [NX]" "Brain RNA - cerebellum [NX]" "Brain RNA - cerebral cortex [NX]" "Brain RNA - hippocampal formation [NX]" "Brain RNA - hypothalamus [NX]" "Brain RNA - midbrain [NX]" "Brain RNA - olfactory region [NX]" "Brain RNA - pons and medulla [NX]" "Brain RNA - thalamus [NX]" ADCYAP1 PACAP ENSG00000141433 "Adenylate cyclase activating polypeptide 1" P18509 18 904943-912172 "Predicted secreted proteins" Neurogenesis Hormone "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 33.8;lymphoid tissue: 16.5" "Cell line enriched" "Detected in some" 12 "SCLC-21H: 19.8" "Cancer enhanced" "Detected in some" "pancreatic cancer: 3.2" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA065887 Supported Supported "Secreted in other tissues" "HPA065887: " "unprognostic (2.68e-1)" "unprognostic (1.83e-2)" "unprognostic (7.09e-2)" "unprognostic (4.04e-2)" "unprognostic (2.23e-1)" "unprognostic (3.87e-4)" "unprognostic (9.58e-3)" "unprognostic (1.00e-1)" "unprognostic (2.34e-1)" "unprognostic (6.86e-2)" "unprognostic (4.16e-2)" "unprognostic (9.94e-2)" "prognostic favourable (2.91e-6)" "unprognostic (2.24e-3)" "unprognostic (9.22e-2)" "unprognostic (1.74e-1)" "unprognostic (5.74e-4)" 2.1 0.5 2.5 16.5 7.7 0.1 1.6 2.1 12.5 3.4 2.6 0.8 0.0 0.1 4.0 0.1 2.2 0.5 12.3 1.0 1.2 18.4 0.6 0.3 1.7 1.6 2.8 6.2 0.2 7.7 0.1 4.5 0.3 33.8 1.4 1.4 2.5 2.2 1.0 0.3 0.9 1.3 1.5 5.9 0.2 1.8 3.6 0.2 0.1 0.3 0.0 1.4 3.1 1.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.2 0.8 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 19.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.5 7.7 2.1 12.1 1.2 18.4 2.8 6.2 33.8 0.2 AGRP "Agrt, ART, ASIP2" ENSG00000159723 "Agouti related neuropeptide" O00253 16 67482571-67483813 "Disease related genes, Plasma proteins, Predicted secreted proteins" "Disease mutation, Obesity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 19.4;epididymis: 49.8" "Cell line enhanced" "Detected in some" "CACO-2: 2.6;CAPAN-2: 2.7;HeLa: 1.5;Hep G2: 2.1;HMC-1: 1.8" "Low cancer specificity" "Detected in single" "Region enriched" "Detected in some" 13 "hypothalamus: 19.4" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Region enriched" "Detected in single" 16 "hypothalamus: 18.9" "Region enhanced" "Detected in some" "hypothalamus: 3.9" HPA041017 Enhanced Supported "Secreted in other tissues" "HPA041017: AB_10795498" "unprognostic (1.32e-1)" "unprognostic (6.26e-2)" "unprognostic (1.13e-1)" "unprognostic (4.16e-1)" "unprognostic (3.15e-1)" "unprognostic (1.10e-1)" "unprognostic (3.61e-1)" "unprognostic (3.34e-1)" "unprognostic (4.68e-1)" "unprognostic (1.29e-1)" "unprognostic (6.74e-2)" "unprognostic (3.17e-1)" "unprognostic (2.80e-1)" "unprognostic (1.72e-1)" "unprognostic (5.63e-2)" "unprognostic (1.09e-1)" "unprognostic (1.18e-2)" 0.1 9.6 0.1 0.1 1.4 0.0 0.1 0.1 0.2 0.1 0.1 0.3 0.1 0.0 0.1 49.8 0.1 0.0 0.1 0.1 0.1 19.4 0.5 0.1 2.1 0.3 0.1 0.3 0.1 0.1 0.0 0.4 0.1 0.2 0.1 0.0 0.3 0.5 0.1 0.1 0.4 0.1 0.1 0.3 0.3 0.1 1.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 2.2 2.1 1.4 3.8 0.3 3.2 1.0 0.1 0.0 0.4 1.4 0.0 0.0 0.6 0.0 0.0 0.0 0.0 2.6 2.7 0.8 0.2 0.0 0.3 0.3 0.0 0.0 0.0 0.0 0.4 1.5 2.1 0.0 0.0 1.8 0.6 0.0 0.0 0.0 0.0 0.1 0.9 0.0 0.0 0.2 0.5 0.0 0.0 0.0 0.0 0.3 0.3 0.7 0.0 0.1 0.0 0.0 0.0 0.2 0.3 0.0 0.5 0.2 0.0 0.1 1.0 0.5 0.9 0.0 0.4 0.3 0.0 3.8 1.4 3.2 2.3 1.6 2.2 0.8 1.1 1.5 1.9 2.1 2.2 0.6 0.3 1.2 2.1 1.3 1.0 0.1 1.4 0.1 0.2 0.1 19.4 0.1 0.3 0.2 0.1 ARHGAP36 FLJ30058 ENSG00000147256 "Rho GTPase activating protein 36" Q6ZRI8 X 131058242-131089883 "Predicted intracellular proteins" "GTPase activation" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "adrenal gland: 58.4;brain: 25.5;pituitary gland: 50.3" "Cell line enriched" "Detected in single" 164 "SH-SY5Y: 62.9" "Cancer enriched" "Detected in some" 21 "thyroid cancer: 62.5" "Region enriched" "Detected in many" 5 "hypothalamus: 25.5" "Not detected" "Not detected" "Not detected" "Not detected" "Region enhanced" "Detected in many" "hypothalamus: 104.3" "Group enriched" "Detected in many" 5 "basal ganglia: 19.8;hypothalamus: 57.8;midbrain: 27.1;pons and medulla: 20.1" "HPA002064, HPA076209" Enhanced Approved "Nucleoplasm,Vesicles,Plasma membrane" Nucleoplasm "Vesicles, Plasma membrane" "HPA002064: AB_1078891, HPA076209: " "unprognostic (2.92e-2)" "unprognostic (7.71e-9)" "unprognostic (2.19e-1)" "unprognostic (8.15e-2)" "unprognostic (1.67e-1)" "unprognostic (1.78e-1)" "unprognostic (2.73e-1)" "unprognostic (1.40e-2)" "unprognostic (1.34e-2)" "unprognostic (2.31e-1)" 6.9 58.4 1.4 0.2 3.6 0.1 1.0 0.0 2.7 0.5 0.2 0.0 0.0 0.1 0.1 2.0 0.3 0.2 0.2 0.1 1.0 25.5 0.1 0.1 0.1 0.1 0.5 0.0 0.1 0.1 0.1 50.3 0.3 5.4 0.3 0.2 0.6 0.2 0.2 13.7 0.1 0.1 0.1 0.8 0.1 0.2 0.6 0.0 0.5 0.5 4.0 0.5 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 62.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 3.6 0.0 0.4 1.0 25.5 0.5 0.0 5.4 0.0 AVP "ADH, ARVP" ENSG00000101200 "Arginine vasopressin" P01185 20 3082556-3084724 "Disease related genes, Predicted secreted proteins" "Hormone, Vasoactive, Vasoconstrictor" "Diabetes insipidus, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 44 "brain: 270.1" "Cell line enriched" "Detected in single" 13 "NB-4: 6.9" "Not detected" "Not detected" "Region enriched" "Detected in many" 18 "hypothalamus: 270.1" "Cell type enriched" "Detected in some" 6 "eosinophil: 6.1" "Lineage enriched" "Detected in many" 6 "granulocytes: 6.1" "Region enriched" "Detected in some" 10 "hypothalamus: 273.6" "Group enriched" "Detected in some" 645 "basal ganglia: 1065.4;hypothalamus: 1058.2" "CAB025318, HPA071892" Enhanced Supported "Secreted to blood" 19255 "CAB025318: , HPA071892: " "unprognostic (1.15e-1)" "unprognostic (2.61e-1)" 0.7 0.9 11.7 0.4 15.0 4.2 0.0 0.0 0.9 0.0 0.1 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.4 270.1 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.0 0.0 0.8 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 1.6 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.1 0.0 0.0 1.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.4 0.0 0.0 0.0 0.0 1.0 0.1 11.7 15.0 0.0 0.9 3.4 270.1 0.0 0.0 0.8 0.0 CALCR CTR ENSG00000004948 "Calcitonin receptor" 7 93424487-93574730 "Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 10.8;kidney: 7.5" "Group enriched" "Detected in some" 6 "MCF7: 2.6;RPTEC TERT1: 4.5;T-47d: 8.6" "Cancer enriched" "Detected in single" 5 "renal cancer: 1.1" "Region enhanced" "Detected in many" "hypothalamus: 10.8" "Cell type enhanced" "Detected in single" "classical monocyte: 1.1" "Lineage enhanced" "Detected in single" "monocytes: 1.1" "Group enriched" "Detected in some" 5 "basal ganglia: 6.7;hypothalamus: 28.7" "Low region specificity" "Detected in all" "HPA028962, HPA061428" Enhanced Supported "HPA028962: AB_10602339, HPA061428: AB_2732661" "unprognostic (1.95e-1)" "unprognostic (2.43e-1)" "unprognostic (3.88e-2)" "unprognostic (1.88e-1)" "unprognostic (1.55e-2)" "unprognostic (3.43e-1)" "unprognostic (7.73e-5)" "unprognostic (1.64e-1)" "unprognostic (9.24e-3)" "unprognostic (8.70e-2)" "unprognostic (1.86e-2)" "unprognostic (6.68e-2)" "unprognostic (2.71e-3)" "unprognostic (1.46e-3)" "unprognostic (1.69e-1)" "unprognostic (2.49e-4)" "unprognostic (1.05e-2)" 0.3 0.7 1.4 0.0 2.1 0.0 1.3 0.1 1.5 0.5 0.2 0.0 0.0 0.1 0.1 0.5 0.3 0.1 0.4 0.4 2.1 10.8 7.5 0.1 0.9 0.0 0.8 0.0 0.7 0.1 0.3 3.2 2.1 5.9 0.1 0.2 0.2 1.4 0.0 3.7 0.1 0.2 0.3 2.5 0.1 0.1 2.3 0.7 0.0 0.1 2.5 0.7 0.1 0.1 0.0 0.4 0.0 1.1 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 2.6 0.0 0.0 0.5 0.0 0.0 0.0 0.0 4.5 0.0 0.0 0.0 0.0 0.2 0.0 8.6 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.8 0.0 0.0 0.0 0.2 0.0 1.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 1.4 2.1 0.1 1.5 2.1 10.8 0.8 0.0 5.9 0.7 CALY "CALCYON, DRD1IP, NSG3" ENSG00000130643 "Calcyon neuron specific vesicular protein" Q9NYX4 10 133324072-133336935 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" Endocytosis "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 9 "adrenal gland: 26.5;brain: 98.9;pituitary gland: 47.7" "Cell line enhanced" "Detected in some" "SH-SY5Y: 2.7;U-266/70: 2.6" "Group enriched" "Detected in some" 14 "glioma: 1.7;pancreatic cancer: 7.7" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "memory CD8 T-cell: 1.3;naive CD4 T-cell: 1.0" "Lineage enriched" "Detected in single" 14 "T-cells: 1.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA042283 Enhanced "HPA042283: AB_10794417" "unprognostic (1.43e-2)" "unprognostic (7.84e-2)" "unprognostic (3.77e-3)" "unprognostic (1.41e-2)" "unprognostic (7.32e-2)" "unprognostic (9.81e-3)" "unprognostic (2.56e-1)" "unprognostic (7.48e-2)" "unprognostic (1.36e-1)" "unprognostic (1.18e-1)" "prognostic favourable (3.54e-4)" "unprognostic (1.23e-2)" "unprognostic (4.19e-10)" "unprognostic (8.04e-3)" "unprognostic (1.29e-1)" "unprognostic (3.60e-1)" "unprognostic (1.63e-1)" 1.8 26.5 27.1 2.7 57.4 1.8 1.8 12.7 67.1 1.7 2.6 3.6 0.0 5.0 1.7 1.9 1.8 2.0 1.8 1.7 31.8 98.9 1.7 1.7 1.9 2.0 25.1 39.8 1.7 6.3 1.7 47.7 1.7 33.9 1.8 2.4 0.7 2.1 2.0 1.7 1.9 3.8 2.1 14.3 1.9 4.1 4.3 4.8 0.0 1.9 0.0 1.9 1.7 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.6 0.1 0.8 0.3 0.0 0.0 0.0 0.3 0.6 0.6 0.0 0.0 0.0 0.0 0.5 0.5 0.0 0.1 0.3 0.0 0.0 0.3 0.0 0.1 0.0 0.8 1.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.1 1.0 0.0 1.1 0.0 0.0 0.3 0.0 0.0 0.4 0.1 0.0 0.0 0.0 2.7 0.0 0.0 0.9 0.1 0.0 0.0 0.0 0.3 0.0 0.1 2.6 0.0 0.0 0.3 0.2 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 1.3 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 27.1 57.4 12.7 45.9 31.8 98.9 25.1 39.8 33.9 4.8 CARTPT CART ENSG00000164326 "CART prepropeptide" Q16568 5 71719163-71721048 "FDA approved drug targets, Predicted secreted proteins" "Neuropeptide, Neurotransmitter" "FDA approved drug targets, Obesity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 10 "adrenal gland: 67.5;brain: 101.4" "Group enriched" "Detected in some" 7 "NB-4: 1.0;SH-SY5Y: 3.4" "Cancer enriched" "Detected in many" 9 "breast cancer: 117.7" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Region enhanced" "Detected in many" "hippocampal formation: 179.9" "CAB025515, HPA046278, CAB079776" Enhanced Supported "Secreted to blood" "CAB025515: , CAB079776: , HPA046278: AB_10961570" "unprognostic (1.37e-1)" "unprognostic (1.43e-1)" "unprognostic (2.27e-1)" "unprognostic (3.45e-2)" "unprognostic (6.67e-2)" "prognostic unfavourable (4.36e-4)" "unprognostic (1.14e-1)" 1.6 67.5 8.0 2.8 22.3 0.5 5.8 0.1 29.0 0.5 3.4 2.1 0.0 3.5 0.6 0.9 3.5 0.7 0.6 0.5 31.1 101.4 0.5 0.5 0.5 0.5 1.0 4.5 0.5 5.3 0.5 1.7 0.5 54.1 3.3 3.1 1.6 0.5 0.5 0.5 0.5 1.4 8.1 8.6 0.5 3.4 1.9 9.7 0.0 3.4 0.0 0.5 0.5 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.0 22.3 0.1 29.0 31.1 101.4 1.0 4.5 54.1 9.7 CCK ENSG00000187094 Cholecystokinin P06307 3 42257825-42266207 "Plasma proteins, Predicted secreted proteins" Hormone "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "brain: 95.1;intestine: 71.6" "Group enriched" "Detected in some" 7 "CAPAN-2: 8.7;RPTEC TERT1: 22.7" "Group enriched" "Detected in many" 5 "glioma: 4.0;pancreatic cancer: 1.8;prostate cancer: 3.5;stomach cancer: 1.0" "Group enriched" "Detected in many" 5 "amygdala: 59.0;basal ganglia: 29.8;cerebral cortex: 95.1;hippocampal formation: 35.8;olfactory region: 26.9" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Region enhanced" "Detected in all" "cerebral cortex: 565.3" "HPA045039, HPA069515" Enhanced Supported "Secreted to blood" "HPA045039: , HPA069515: " "unprognostic (3.36e-1)" "unprognostic (1.58e-1)" "unprognostic (1.92e-1)" "unprognostic (1.40e-3)" "unprognostic (1.04e-1)" "unprognostic (1.70e-1)" "unprognostic (2.39e-3)" "unprognostic (1.97e-2)" "unprognostic (3.91e-1)" "unprognostic (8.77e-2)" "unprognostic (1.35e-1)" "unprognostic (2.42e-1)" "unprognostic (1.37e-1)" "unprognostic (5.10e-2)" 0.9 1.1 59.0 1.1 29.8 0.8 0.9 0.2 95.1 0.8 11.3 1.4 0.0 71.6 0.8 0.8 0.9 0.9 0.9 0.9 35.8 10.8 0.8 0.9 1.1 0.8 8.0 26.9 0.8 1.1 0.8 4.1 9.4 1.3 13.5 0.9 0.0 0.8 1.0 0.8 0.9 10.5 1.0 1.3 0.8 1.7 1.7 0.5 0.0 0.8 0.0 0.8 0.8 0.2 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.2 0.7 0.0 0.0 0.0 0.0 8.7 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.4 0.1 0.0 0.0 0.0 0.0 0.1 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.9 22.7 0.1 0.2 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 59.0 29.8 0.2 95.1 35.8 10.8 8.0 26.9 1.3 0.5 CNGA3 "ACHM2, CCNC1, CCNCa, CNCG3, CNG3" ENSG00000144191 "Cyclic nucleotide gated channel alpha 3" Q16281 2 98346155-98398601 "Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Sensory transduction, Transport, Vision" "Ion channel, Ligand-gated ion channel" "Disease mutation, Leber congenital amaurosis" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "pituitary gland: 32.0" "Cell line enriched" "Detected in some" 7 "U-87 MG: 12.5" "Cancer enriched" "Detected in some" 9 "glioma: 7.9" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 6 "basal ganglia: 1.9;hypothalamus: 2.2" "Not detected" "Not detected" "HPA049378, CAB079025" Approved Approved "CAB079025: , HPA049378: " "unprognostic (2.34e-2)" "unprognostic (1.83e-2)" "unprognostic (4.96e-2)" "unprognostic (4.81e-2)" "unprognostic (1.13e-1)" "unprognostic (2.18e-1)" "unprognostic (4.17e-4)" "unprognostic (4.65e-2)" "unprognostic (1.86e-3)" "unprognostic (2.88e-1)" "unprognostic (3.85e-3)" "unprognostic (8.98e-2)" "unprognostic (5.90e-2)" "unprognostic (3.71e-2)" 0.1 0.0 0.3 1.4 0.7 0.0 0.7 0.1 2.9 0.1 6.1 2.4 0.1 2.8 0.1 0.1 4.6 0.8 0.4 0.1 1.2 4.0 0.1 0.1 0.2 0.1 0.8 0.4 0.1 1.5 0.0 32.0 0.1 4.9 0.1 3.2 1.2 0.2 0.5 0.1 0.0 4.0 2.2 4.3 0.1 3.0 1.1 0.3 0.1 0.1 0.1 0.1 1.6 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 1.7 0.0 0.0 0.0 0.0 12.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.7 0.1 1.5 1.2 4.0 0.8 0.4 4.9 0.3 CRABP1 "CRABP, CRABP-I, CRABPI, RBP5" ENSG00000166426 "Cellular retinoic acid binding protein 1" P29762 15 78340324-78348230 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" Transport "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 40.1;retina: 73.2;thyroid gland: 80.6" "Group enriched" "Detected in some" 8 "AF22: 143.3;NTERA-2: 42.9" "Cancer enhanced" "Detected in many" "ovarian cancer: 117.2" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 13 "myeloid DC: 1.2" "Lineage enriched" "Detected in single" 13 "dendritic cells: 1.2" "Group enriched" "Detected in many" 5 "amygdala: 6.6;basal ganglia: 20.9;hypothalamus: 15.5;olfactory region: 15.7;pons and medulla: 7.8" "Low region specificity" "Detected in some" HPA017203 Enhanced Supported "HPA017203: AB_1846512" "unprognostic (1.23e-1)" "unprognostic (3.76e-3)" "unprognostic (1.46e-1)" "prognostic unfavourable (4.72e-4)" "unprognostic (2.01e-1)" "unprognostic (4.35e-2)" "unprognostic (1.05e-1)" "unprognostic (1.35e-1)" "unprognostic (2.45e-2)" "unprognostic (9.79e-2)" "unprognostic (1.21e-1)" "unprognostic (2.79e-2)" "unprognostic (9.37e-2)" "unprognostic (2.17e-1)" "unprognostic (1.07e-1)" "unprognostic (2.69e-1)" 0.7 1.3 6.3 1.8 25.6 0.6 24.8 2.8 12.4 1.2 1.9 3.3 0.3 0.9 1.5 1.9 0.7 0.5 1.2 0.7 1.1 21.9 4.2 0.5 0.8 0.6 16.9 4.5 0.7 0.7 0.5 6.3 7.0 40.1 1.0 1.3 73.2 0.6 24.8 0.5 12.3 2.3 1.3 7.3 21.1 1.9 0.6 2.4 0.4 80.6 2.4 1.0 0.7 0.4 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 143.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.7 0.1 0.0 0.9 0.0 0.0 1.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 7.6 0.0 42.9 0.1 0.0 0.0 0.0 0.0 0.2 12.0 8.1 0.0 0.0 0.0 0.2 4.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.3 25.6 2.8 12.4 1.1 21.9 16.9 4.5 40.1 2.4 DDX25 GRTH ENSG00000109832 "DEAD-box helicase 25" Q9UHL0 11 125903348-125943702 "Enzymes, Plasma proteins, Predicted intracellular proteins" "Differentiation, mRNA transport, Spermatogenesis, Translation regulation, Transport" "Developmental protein, Helicase, Hydrolase, RNA-binding" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "brain: 17.3;testis: 64.2" "Group enriched" "Detected in some" 4 "NTERA-2: 13.6;SCLC-21H: 11.0" "Cancer enhanced" "Detected in some" "glioma: 1.0" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "neutrophil: 3.3" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA020137 Enhanced "HPA020137: AB_1847552" "unprognostic (5.78e-3)" "unprognostic (9.75e-3)" "unprognostic (7.93e-2)" "unprognostic (5.09e-3)" "unprognostic (1.11e-2)" "unprognostic (1.78e-2)" "unprognostic (1.54e-1)" "unprognostic (2.91e-3)" "unprognostic (6.24e-5)" "unprognostic (2.57e-1)" "unprognostic (2.44e-3)" "unprognostic (3.89e-1)" "unprognostic (3.44e-3)" "unprognostic (1.44e-1)" "unprognostic (1.76e-1)" "unprognostic (9.72e-2)" "unprognostic (1.69e-1)" 0.7 2.8 8.7 0.8 13.2 0.9 0.8 7.9 17.3 0.8 0.8 2.0 0.0 1.0 0.9 0.9 0.8 0.9 0.8 0.7 8.4 7.1 2.7 0.8 0.8 0.8 4.8 8.9 1.2 1.8 2.6 7.1 0.9 5.9 0.9 0.8 2.3 0.8 1.0 0.8 1.6 0.8 0.7 3.4 0.9 1.0 64.2 3.0 0.0 4.3 0.0 0.8 0.7 0.2 0.6 0.5 3.3 0.3 1.3 0.5 0.1 0.0 0.0 2.7 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.9 0.0 0.2 1.5 0.2 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.3 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.4 0.0 0.6 2.0 0.1 13.6 0.0 0.5 0.0 0.0 0.0 0.1 11.0 2.5 0.2 0.0 1.9 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.0 0.0 0.8 2.1 0.3 0.6 0.3 0.2 0.2 0.4 0.5 0.2 0.1 0.6 0.4 0.3 3.3 1.3 0.2 0.5 0.1 0.1 8.7 13.2 7.9 12.5 8.4 7.1 4.8 8.9 5.9 3.0 ECEL1 "DINE, XCE" ENSG00000171551 "Endothelin converting enzyme like 1" O95672 2 232479827-232487828 "Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Hydrolase, Metalloprotease, Protease" "Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 28.6;ovary: 57.1" "Group enriched" "Detected in some" 6 "AN3-CA: 29.4;HeLa: 15.0" "Cancer enhanced" "Detected in many" "endometrial cancer: 12.9" "Region enriched" "Detected in many" 5 "hypothalamus: 28.6" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA067560, HPA069756, HPA077424" Approved Supported Approved "Nucleoplasm,Nuclear membrane,Nucleoli" Nucleoplasm "Nuclear membrane, Nucleoli" "HPA067560: , HPA069756: , HPA077424: " "unprognostic (1.21e-2)" "unprognostic (1.06e-2)" "unprognostic (4.39e-1)" "unprognostic (4.62e-3)" "unprognostic (2.80e-1)" "unprognostic (9.96e-4)" "unprognostic (7.56e-3)" "unprognostic (1.22e-1)" "unprognostic (9.89e-3)" "unprognostic (8.49e-2)" "unprognostic (1.54e-1)" "unprognostic (2.89e-1)" "unprognostic (1.24e-5)" "unprognostic (3.09e-2)" "unprognostic (3.68e-1)" "unprognostic (7.84e-2)" "unprognostic (5.45e-2)" 0.9 2.6 0.5 0.9 4.0 0.2 0.4 0.7 1.2 0.3 0.4 0.5 0.1 0.3 0.6 4.9 0.3 1.7 1.0 1.1 0.1 28.6 1.0 0.7 0.2 1.2 0.3 0.1 57.1 0.6 0.3 8.9 0.4 5.5 0.3 0.2 11.5 0.3 1.2 1.8 0.3 0.3 1.1 4.5 2.0 0.3 0.8 1.6 0.1 0.5 0.3 0.5 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 29.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.4 0.3 0.0 0.0 0.4 0.0 0.0 0.0 2.6 0.0 15.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 2.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 4.0 0.7 1.2 0.1 28.6 0.3 0.1 5.5 1.6 FEZF1 ZNF312B ENSG00000128610 "FEZ family zinc finger 1" A0PJY2 7 122301394-122310691 "Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Neurogenesis, Transcription, Transcription regulation" "Developmental protein, DNA-binding, Repressor" "Disease mutation, Hypogonadotropic hypogonadism, Kallmann syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "brain: 16.7;testis: 11.0" "Group enriched" "Detected in some" 10 "NTERA-2: 57.4;SCLC-21H: 25.1" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in many" "hypothalamus: 16.7" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in single" 11 "hypothalamus: 13.7" "Region enriched" "Detected in single" 9 "hypothalamus: 6.9" "HPA064639, HPA073693" Approved Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA064639: , HPA073693: " "unprognostic (8.48e-2)" "unprognostic (3.41e-2)" "unprognostic (3.64e-1)" "unprognostic (3.43e-2)" "unprognostic (4.17e-1)" "unprognostic (4.10e-2)" "unprognostic (2.64e-3)" "unprognostic (2.54e-1)" "unprognostic (1.34e-1)" "unprognostic (2.96e-2)" "unprognostic (2.55e-1)" "unprognostic (1.48e-2)" 0.6 0.2 6.4 0.2 4.9 0.2 0.2 0.0 2.0 0.2 0.2 0.0 0.0 0.2 0.2 0.2 0.2 0.2 0.2 0.3 1.0 16.7 0.2 0.2 0.2 0.2 2.0 0.0 0.3 0.2 0.2 3.1 0.2 0.0 0.3 0.2 1.4 0.6 0.2 0.2 0.3 0.2 0.2 0.0 0.2 0.3 11.0 3.5 0.0 0.2 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 4.2 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 0.0 0.0 0.0 57.4 1.0 0.0 0.0 0.0 0.0 0.1 25.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 2.7 0.1 0.0 0.0 0.7 0.0 0.0 0.4 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.4 4.9 0.0 2.0 1.0 16.7 2.0 0.0 0.0 3.5 GAL "GAL-GMAP, GALN, GLNN, GMAP" ENSG00000069482 "Galanin and GMAP prepropeptide" P22466 11 68683779-68691175 "Disease related genes, Plasma proteins, Predicted secreted proteins" "Hormone, Neuropeptide" "Disease mutation, Epilepsy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 8 "pituitary gland: 149.9" "Cell line enhanced" "Detected in some" "CACO-2: 46.9;HEK 293: 21.9;K-562: 24.3;NB-4: 86.7;SH-SY5Y: 35.0" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in some" 8 "hypothalamus: 18.8" "Cell type enriched" "Detected in single" 15 "intermediate monocyte: 1.5" "Lineage enriched" "Detected in single" 15 "monocytes: 1.5" "Region enhanced" "Detected in many" "hypothalamus: 111.6" "Low region specificity" "Detected in all" "HPA049864, CAB079779" Enhanced Supported Supported "Golgi apparatus,Vesicles" "Secreted to blood" 60030 "Golgi apparatus" Vesicles "CAB079779: , HPA049864: " "unprognostic (8.56e-2)" "unprognostic (1.45e-2)" "unprognostic (7.50e-2)" "prognostic unfavourable (1.22e-4)" "unprognostic (2.70e-1)" "unprognostic (2.27e-2)" "unprognostic (8.07e-3)" "prognostic unfavourable (8.17e-4)" "unprognostic (5.98e-2)" "unprognostic (1.07e-2)" "unprognostic (8.84e-2)" "unprognostic (7.42e-2)" "unprognostic (1.20e-1)" "unprognostic (8.85e-2)" "unprognostic (7.88e-2)" "unprognostic (5.38e-2)" "unprognostic (3.24e-2)" 2.8 0.2 0.1 14.8 0.5 0.4 4.5 0.6 2.0 0.2 6.0 0.1 0.4 1.7 0.2 0.7 0.7 0.2 0.3 0.6 1.3 18.8 0.3 0.2 0.2 0.1 0.2 0.6 0.2 2.9 0.0 149.9 0.9 2.2 0.7 4.1 0.6 0.5 1.8 0.3 4.5 2.2 9.7 0.3 0.2 1.5 0.5 0.4 0.7 0.2 0.4 0.3 1.5 0.3 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 1.9 0.2 0.0 0.0 0.0 4.4 6.6 0.0 0.1 0.0 46.9 1.7 0.0 2.4 0.2 0.0 0.0 0.0 0.0 0.0 21.9 1.1 14.1 0.0 0.2 0.6 0.0 0.3 0.7 0.0 0.0 1.1 24.3 0.0 0.0 13.3 0.0 86.7 11.2 4.2 0.0 0.0 8.9 0.1 0.0 9.1 35.0 4.6 0.2 0.0 0.2 10.2 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.5 0.6 0.7 1.3 18.8 0.2 0.6 2.2 0.4 GATA2 NFE1B ENSG00000179348 "GATA binding protein 2" P23769 3 128479427-128493185 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Phagocytosis, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 81.2;ductus deferens: 85.8;seminal vesicle: 209.1" "Cell line enhanced" "Detected in many" "BEWO: 55.8;HEL: 68.8;HMC-1: 37.2;SH-SY5Y: 65.0" "Cancer enhanced" "Detected in all" "prostate cancer: 36.7" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 339 "basophil: 81.2" "Lineage enriched" "Detected in single" 813 "granulocytes: 81.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA005633, CAB024847" Enhanced Supported Nucleoplasm Nucleoplasm "CAB024847: , HPA005633: AB_1078954" "unprognostic (1.71e-1)" "unprognostic (8.90e-2)" "unprognostic (1.12e-1)" "unprognostic (8.61e-2)" "unprognostic (8.67e-2)" "unprognostic (4.17e-2)" "unprognostic (5.96e-3)" "unprognostic (7.30e-2)" "unprognostic (3.98e-2)" "unprognostic (4.12e-2)" "unprognostic (3.58e-2)" "unprognostic (3.04e-1)" "prognostic favourable (2.04e-4)" "unprognostic (2.50e-1)" "unprognostic (8.07e-2)" "unprognostic (2.08e-1)" "prognostic favourable (5.22e-5)" 7.0 6.2 2.1 1.5 2.4 2.5 7.9 1.2 1.9 22.4 2.8 1.4 85.8 2.5 20.6 5.4 3.2 23.0 9.7 4.8 1.5 1.0 7.6 0.6 16.1 2.2 1.8 1.1 4.6 5.8 3.4 4.5 51.8 2.4 27.8 1.8 6.1 1.9 209.1 3.5 4.1 3.4 8.4 1.4 5.1 2.9 2.7 1.5 0.4 3.3 2.7 1.5 22.4 12.4 0.0 0.0 81.2 0.0 0.0 0.0 0.4 4.6 1.1 0.2 3.1 0.4 0.1 55.8 10.4 8.9 3.6 1.3 1.9 2.0 0.1 2.9 6.1 4.9 2.9 0.0 1.5 0.0 1.6 68.8 7.6 3.0 0.8 6.9 37.2 0.0 0.0 0.1 0.0 5.6 18.0 0.1 0.0 1.7 0.0 14.1 0.2 0.3 0.0 1.3 0.0 0.1 4.1 4.3 65.0 2.6 13.8 0.4 2.6 2.8 10.0 0.2 0.1 2.5 1.4 0.0 0.0 0.0 0.1 0.4 0.7 81.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 2.1 2.4 1.2 1.9 1.5 1.0 1.8 1.1 2.4 1.5 GNRH1 "GNRH, GRH, LHRH" ENSG00000147437 "Gonadotropin releasing hormone 1" P01148 8 25419260-25424654 "Disease related genes, Predicted secreted proteins" Hormone "Disease mutation, Hypogonadotropic hypogonadism, Kallmann syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 23.5" "Cell line enhanced" "Detected in many" "SCLC-21H: 21.0" "Low cancer specificity" "Detected in many" "Group enriched" "Detected in all" 4 "basal ganglia: 23.5;cerebellum: 6.9" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Group enriched" "Detected in many" 4 "basal ganglia: 20.8;hypothalamus: 14.2;olfactory region: 8.3" "Group enriched" "Detected in some" 30 "basal ganglia: 21.7;hypothalamus: 66.0" HPA027532 Supported "Secreted to blood" "HPA027532: AB_10612111" "unprognostic (6.49e-3)" "unprognostic (7.62e-2)" "unprognostic (2.90e-1)" "unprognostic (5.06e-2)" "unprognostic (1.35e-1)" "unprognostic (3.53e-4)" "unprognostic (7.80e-3)" "unprognostic (2.97e-2)" "unprognostic (1.39e-1)" "unprognostic (7.99e-2)" "unprognostic (3.45e-1)" "unprognostic (1.44e-1)" "prognostic unfavourable (8.08e-9)" "unprognostic (7.98e-3)" "unprognostic (5.11e-2)" "unprognostic (3.49e-1)" "unprognostic (3.68e-2)" 2.0 1.3 1.7 1.7 23.5 3.6 5.0 6.9 2.3 2.4 2.6 2.1 1.7 2.6 2.5 6.7 2.3 1.9 2.8 2.3 1.7 3.7 2.3 1.7 2.7 2.8 1.7 1.7 4.3 2.8 0.8 2.0 1.9 1.7 3.6 2.5 1.7 3.3 2.4 4.0 12.6 2.9 1.7 1.7 3.1 1.5 1.7 3.2 1.7 1.8 1.7 2.3 1.7 3.9 0.9 1.1 1.7 0.3 0.2 1.9 0.1 1.0 1.7 4.5 2.4 1.6 5.3 2.0 4.0 1.6 1.2 1.9 1.7 1.2 1.3 0.9 2.3 4.0 1.3 0.3 2.9 1.8 2.3 1.4 5.9 1.7 1.3 0.2 1.5 3.1 2.4 0.9 0.8 1.0 1.6 1.3 2.0 0.7 1.4 3.1 1.6 0.5 0.9 0.6 0.6 1.2 0.7 21.0 0.8 1.1 0.8 1.4 0.8 1.9 3.7 3.5 1.7 4.0 1.5 0.2 0.2 1.9 1.7 1.1 1.5 0.0 0.0 0.0 1.9 0.1 0.8 0.3 0.2 0.6 0.1 0.9 0.4 0.3 1.7 0.2 0.3 1.1 1.6 0.1 1.7 23.5 6.9 2.3 1.7 3.7 1.7 1.7 1.7 3.2 GRIN2D "EB11, GluN2D, NMDAR2D, NR2D" ENSG00000105464 "Glutamate ionotropic receptor NMDA type subunit 2D" O15399 19 48394875-48444931 "Disease related genes, FDA approved drug targets, Predicted membrane proteins" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 6.9" "Cell line enhanced" "Detected in many" "A549: 12.7;EFO-21: 8.8;HMC-1: 21.6;NB-4: 12.7;SK-BR-3: 11.3" "Low cancer specificity" "Detected in many" "Cell type enhanced" "Detected in single" "classical monocyte: 1.2" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB009006 Approved "CAB009006: AB_2279191" "unprognostic (9.96e-2)" "unprognostic (6.98e-2)" "unprognostic (1.17e-1)" "unprognostic (5.08e-3)" "unprognostic (1.46e-1)" "unprognostic (4.17e-1)" "unprognostic (1.43e-4)" "unprognostic (7.84e-2)" "unprognostic (2.72e-1)" "unprognostic (2.23e-3)" "unprognostic (1.57e-1)" "unprognostic (1.80e-1)" "unprognostic (6.66e-13)" "unprognostic (2.15e-2)" "unprognostic (1.92e-2)" "unprognostic (1.26e-3)" "unprognostic (1.14e-1)" 0.5 0.1 4.1 1.1 1.7 0.1 0.1 2.0 5.0 0.1 0.6 1.8 0.0 0.1 0.0 0.2 1.1 0.3 2.4 6.9 0.0 0.0 0.4 0.3 3.1 0.0 0.0 1.4 0.0 3.2 0.8 0.0 0.5 0.1 0.1 1.0 2.8 0.4 1.1 0.4 0.7 1.6 1.0 0.1 0.5 0.1 0.0 0.8 0.0 1.2 0.0 0.0 0.0 1.0 12.7 0.3 0.0 1.0 2.7 7.5 1.5 0.0 0.4 0.1 0.9 7.4 0.3 8.8 0.8 0.1 0.1 0.1 0.2 1.3 0.3 3.8 0.2 1.6 1.4 0.3 21.6 1.0 0.0 0.7 0.0 0.3 7.1 0.4 0.0 2.2 0.0 12.7 0.4 0.2 0.0 0.0 0.1 0.2 0.0 1.3 1.2 0.5 11.3 0.1 0.0 4.8 4.2 0.0 0.1 0.0 0.0 2.0 2.3 0.0 0.0 1.4 0.1 0.0 1.2 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 HCRT "OX, PPOX" ENSG00000161610 "Hypocretin neuropeptide precursor" O43612 17 42184060-42185452 "Disease related genes, Predicted secreted proteins" Neuropeptide "Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 31 "brain: 84.3" "Cell line enhanced" "Detected in some" "HDLM-2: 1.9;Karpas-707: 1.0;RPMI-8226: 3.6" "Cancer enhanced" "Detected in single" "glioma: 0.5" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 4 "B-cells: 2.7;granulocytes: 2.3;T-cells: 2.2" "Region enriched" "Detected in some" 5 "hypothalamus: 110.5" "Region enriched" "Detected in single" 56 "hypothalamus: 152.0" "HPA064801, CAB079778" Enhanced Supported "Secreted to blood" "CAB079778: , HPA064801: " "unprognostic (3.34e-2)" "unprognostic (7.76e-5)" "unprognostic (3.21e-2)" "unprognostic (3.01e-2)" "unprognostic (2.20e-2)" "unprognostic (1.41e-1)" "unprognostic (1.23e-1)" 0.9 0.0 0.0 1.1 0.2 0.9 0.0 0.0 0.7 0.0 0.5 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 84.3 0.4 0.0 0.0 0.4 0.1 0.3 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.3 0.1 0.3 0.0 0.0 0.0 0.0 2.7 0.4 2.3 0.5 0.4 2.2 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.9 0.9 0.8 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.6 1.0 0.0 0.0 0.8 0.8 0.4 0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.9 0.2 0.7 0.8 0.2 0.0 0.1 0.0 2.3 0.5 0.0 1.2 0.4 2.2 1.5 0.9 1.6 0.4 2.7 1.4 1.3 0.1 0.4 0.2 0.3 0.5 0.1 HCRTR1 OX1R ENSG00000121764 "Hypocretin receptor 1" O43613 1 31617686-31632518 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 8.0" "Cell line enhanced" "Detected in some" "HeLa: 1.7;HUVEC TERT2: 2.9;TIME: 1.6" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in single" "naive B-cell: 1.1" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA014018 Approved "HPA014018: AB_1854810" "unprognostic (2.96e-2)" "unprognostic (2.34e-2)" "unprognostic (7.86e-3)" "unprognostic (3.72e-3)" "unprognostic (2.42e-1)" "unprognostic (3.45e-3)" "unprognostic (2.54e-5)" "unprognostic (3.58e-2)" "unprognostic (4.17e-2)" "unprognostic (1.19e-1)" "unprognostic (2.28e-1)" "unprognostic (2.93e-1)" "unprognostic (3.77e-3)" "unprognostic (2.16e-2)" "unprognostic (1.02e-1)" "unprognostic (1.43e-1)" "unprognostic (1.07e-1)" 3.3 4.3 0.9 0.3 1.4 1.6 2.7 0.7 4.5 0.1 0.3 0.0 0.0 0.2 0.6 0.3 0.7 0.5 0.8 1.8 0.8 4.6 0.5 0.1 0.2 0.6 1.1 0.0 0.5 0.3 0.0 1.7 2.3 8.0 0.5 0.2 0.7 0.5 0.0 2.4 1.1 0.5 0.0 0.5 0.6 0.4 0.4 0.0 0.0 2.9 0.8 0.2 0.6 0.1 1.1 0.2 0.0 0.2 0.2 0.5 0.1 0.4 0.0 0.3 0.1 0.0 0.0 0.7 0.5 0.0 0.0 0.0 0.0 0.6 0.6 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.4 0.3 1.7 0.0 0.0 1.0 0.4 0.0 0.0 0.5 0.0 2.9 0.4 0.2 0.0 0.5 0.1 0.1 0.1 0.0 1.1 0.1 0.0 0.0 0.7 0.1 0.4 0.3 0.2 0.0 0.2 0.0 1.6 0.1 0.2 0.3 0.4 0.5 0.1 0.2 0.0 0.6 1.0 0.0 0.2 0.0 0.5 0.2 0.0 0.1 0.2 0.0 0.1 1.1 0.1 0.1 0.0 0.2 0.1 0.2 0.0 0.1 0.9 1.4 0.7 4.5 0.8 4.6 1.1 0.0 8.0 0.0 HDC ENSG00000140287 "Histidine decarboxylase" P19113 15 50241947-50266026 "Enzymes, Predicted intracellular proteins" "Catecholamine biosynthesis" "Decarboxylase, Lyase" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 8 "blood: 83.5;brain: 36.0;epididymis: 36.9" "Group enriched" "Detected in some" 4 "HEL: 59.8;HMC-1: 143.8" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in single" 52 "hypothalamus: 36.0" "Cell type enriched" "Detected in single" 835 "basophil: 83.5" "Lineage enriched" "Detected in single" 835 "granulocytes: 83.5" "Region enriched" "Detected in many" 5 "hypothalamus: 51.5" "Low region specificity" "Detected in all" HPA038891 Enhanced Approved "Nuclear bodies" "Nuclear bodies" "HPA038891: AB_10673231" "unprognostic (4.97e-2)" "unprognostic (7.42e-2)" "unprognostic (1.43e-4)" "unprognostic (1.08e-1)" "unprognostic (6.16e-2)" "unprognostic (3.93e-7)" "unprognostic (4.18e-5)" "unprognostic (8.79e-3)" "unprognostic (1.48e-1)" "unprognostic (8.46e-2)" "unprognostic (4.60e-2)" "unprognostic (1.05e-1)" "unprognostic (2.53e-1)" "unprognostic (7.20e-2)" "unprognostic (9.78e-2)" "unprognostic (2.15e-1)" "unprognostic (1.50e-1)" 1.7 0.2 0.2 5.1 0.4 2.4 1.1 0.2 0.3 2.7 1.9 0.2 1.2 2.1 3.1 36.9 2.7 0.6 6.6 2.1 0.2 36.0 0.6 0.8 4.9 2.3 0.6 0.1 0.4 0.5 0.3 0.7 0.2 0.3 2.2 1.9 3.0 0.9 1.3 1.8 1.8 2.4 5.4 0.2 0.4 6.9 2.4 0.2 0.4 0.3 0.4 1.7 1.8 2.7 0.0 0.0 83.5 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 59.8 0.0 0.0 0.0 0.1 143.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 22.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 83.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.4 0.2 0.3 0.2 36.0 0.6 0.1 0.3 0.2 HMX2 NKX5-2 ENSG00000188816 "H6 family homeobox 2" A2RU54 10 123148122-123150672 "Predicted intracellular proteins, Transcription factors" "Differentiation, Neurogenesis, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 2.0;brain: 5.1;kidney: 5.5" "Cell line enriched" "Detected in some" 13 "REH: 28.3" "Cancer enhanced" "Detected in single" "cervical cancer: 0.9" "Group enriched" "Detected in some" 41 "hypothalamus: 5.1;pons and medulla: 3.0" "Cell type enhanced" "Detected in single" "naive CD4 T-cell: 2.0" "Lineage enriched" "Detected in single" 21 "T-cells: 2.0" "Region enhanced" "Detected in single" "hypothalamus: 0.6" "Group enriched" "Detected in some" 4 "basal ganglia: 1.1;hypothalamus: 4.0" "CAB013268, CAB022752" Approved "CAB013268: , CAB022752: " "unprognostic (3.98e-2)" "unprognostic (1.00e-3)" "unprognostic (1.44e-1)" "unprognostic (7.18e-2)" "unprognostic (2.73e-2)" "unprognostic (7.64e-2)" "unprognostic (3.29e-1)" "unprognostic (2.10e-3)" "unprognostic (5.29e-1)" "unprognostic (5.01e-2)" "unprognostic (2.25e-1)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.1 5.5 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 3.0 0.4 0.1 0.0 0.0 0.1 0.0 0.0 0.9 0.0 0.0 0.0 0.1 1.2 0.0 0.8 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 1.0 0.0 0.0 1.7 0.0 0.0 0.0 0.3 0.3 0.9 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.4 0.0 0.0 28.3 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 2.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 5.1 0.0 0.0 3.0 0.0 HTR7 5-HT7 ENSG00000148680 "5-hydroxytryptamine receptor 7" P34969 10 90740823-90857698 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, RAS pathway related proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "parathyroid gland: 30.8;testis: 14.3" "Cell line enhanced" "Detected in some" "HBEC3-KT: 8.1;hTCEpi: 7.3;hTERT-HME1: 24.5;LHCN-M2: 9.8;U-87 MG: 7.5;WM-115: 9.3" "Group enriched" "Detected in some" 5 "cervical cancer: 0.9;head and neck cancer: 3.3;lung cancer: 0.9;urothelial cancer: 1.3" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 12 "myeloid DC: 4.6" "Lineage enriched" "Detected in single" 12 "dendritic cells: 4.6" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB022708, HPA073617" Approved Supported "Nuclear speckles,Plasma membrane,Cytosol" "Plasma membrane" "Nuclear speckles, Cytosol" "CAB022708: , HPA073617: " "unprognostic (1.17e-1)" "unprognostic (1.24e-2)" "unprognostic (4.72e-2)" "unprognostic (1.33e-1)" "unprognostic (5.51e-3)" "unprognostic (1.71e-2)" "unprognostic (1.89e-1)" "unprognostic (1.44e-1)" "unprognostic (1.15e-1)" "unprognostic (4.58e-3)" "unprognostic (3.32e-1)" "unprognostic (1.45e-1)" "unprognostic (2.89e-1)" "unprognostic (1.23e-3)" "unprognostic (1.38e-1)" "unprognostic (1.84e-2)" "unprognostic (6.49e-2)" 1.0 0.5 2.4 1.1 2.5 0.5 0.7 0.3 4.3 0.6 0.8 1.7 1.2 0.8 0.4 0.3 1.0 0.4 1.3 0.6 9.9 5.1 0.3 0.6 0.5 0.7 1.7 1.8 0.4 1.4 30.8 0.2 0.5 3.1 1.0 1.2 0.4 0.6 0.3 1.7 0.9 2.2 3.6 1.5 1.3 1.5 14.3 1.0 0.0 0.3 0.1 0.6 3.5 2.1 0.0 4.6 0.0 0.3 0.0 0.2 0.1 0.2 0.0 0.0 0.0 0.1 0.7 0.0 0.5 0.2 0.5 0.7 0.0 0.9 0.0 0.0 0.1 3.3 0.9 8.1 2.0 0.0 0.1 0.0 0.0 0.0 3.8 0.0 0.4 5.8 7.3 2.4 24.5 0.0 0.0 0.0 9.8 0.0 0.0 0.1 0.9 1.2 0.7 0.1 0.0 0.0 0.9 0.3 0.0 0.3 0.0 3.8 0.0 0.2 0.2 4.5 0.0 0.0 6.8 0.0 0.0 0.0 7.5 0.0 9.3 0.0 0.1 0.0 0.1 0.2 0.0 0.0 0.1 0.1 4.6 0.0 0.2 0.2 0.0 0.0 0.3 0.0 0.1 0.1 2.4 2.5 0.3 4.3 9.9 5.1 1.7 1.8 3.1 1.0 KISS1R "AXOR12, GPR54, HOT7T175" ENSG00000116014 "KISS1 receptor" Q969F8 19 917287-921015 "Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease mutation, Hypogonadotropic hypogonadism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 6.8;lymphoid tissue: 12.4" "Cell line enhanced" "Detected in some" "K-562: 10.5;RPMI-8226: 25.7;SCLC-21H: 5.4;SH-SY5Y: 14.4" "Cancer enhanced" "Detected in many" "renal cancer: 3.6" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "naive CD4 T-cell: 2.0;neutrophil: 1.8" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA007156, HPA071913" Approved Supported "Vesicles,Plasma membrane" "Plasma membrane" Vesicles "HPA007156: , HPA071913: " "unprognostic (1.54e-1)" "unprognostic (3.01e-2)" "unprognostic (9.42e-2)" "unprognostic (2.15e-1)" "unprognostic (8.46e-3)" "unprognostic (9.23e-2)" "unprognostic (1.65e-2)" "unprognostic (3.23e-1)" "unprognostic (1.37e-1)" "unprognostic (1.16e-1)" "unprognostic (1.48e-2)" "unprognostic (7.17e-2)" "prognostic unfavourable (3.33e-6)" "unprognostic (1.87e-1)" "unprognostic (8.09e-3)" "unprognostic (1.05e-1)" "unprognostic (2.05e-2)" 0.2 0.2 2.1 2.1 4.1 0.2 0.3 0.1 4.7 0.1 0.3 0.1 0.1 0.4 0.2 0.1 0.1 0.2 0.1 0.1 1.0 6.8 1.4 0.1 0.3 12.4 1.1 0.1 0.4 3.6 0.1 2.0 1.0 0.8 0.2 0.2 0.3 0.3 0.1 0.1 0.1 0.7 0.5 1.0 2.4 0.4 0.1 0.1 0.1 0.1 0.1 0.6 0.5 0.1 0.6 0.0 1.8 0.0 0.0 2.0 0.0 0.0 0.5 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.1 0.0 0.0 0.8 0.0 0.0 0.2 2.8 0.0 0.0 3.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.5 0.0 0.0 0.2 0.1 0.0 0.4 0.3 0.7 0.0 25.7 0.0 0.0 5.4 14.4 0.0 0.0 0.0 0.2 0.6 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.6 0.7 0.0 0.0 0.1 2.0 0.6 1.8 0.0 0.0 0.0 0.1 0.0 2.1 4.1 0.1 1.5 1.0 6.8 1.1 0.1 0.8 0.1 LUZP2 ENSG00000187398 "Leucine zipper protein 2" Q86TE4 11 24496970-25082631 "Predicted intracellular proteins, Predicted secreted proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "adrenal gland: 11.1;brain: 32.7" "Group enriched" "Detected in some" 4 "HaCaT: 14.3;HAP1: 7.1" "Group enriched" "Detected in some" 7 "glioma: 3.5;prostate cancer: 4.5" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "neutrophil: 1.9" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "HPA039007, HPA046161" Enhanced Supported Approved "Nucleoplasm,Plasma membrane,Cytosol" "Secreted in brain" "Nucleoplasm, Cytosol" "Plasma membrane" "HPA039007: , HPA046161: " "unprognostic (4.49e-2)" "unprognostic (2.74e-2)" "unprognostic (8.63e-2)" "unprognostic (3.50e-1)" "unprognostic (5.22e-3)" "unprognostic (3.38e-1)" "unprognostic (4.88e-2)" "unprognostic (5.67e-4)" "unprognostic (2.40e-1)" "unprognostic (5.66e-2)" "unprognostic (6.16e-3)" "unprognostic (4.09e-2)" "unprognostic (5.18e-3)" "unprognostic (9.41e-3)" "unprognostic (4.18e-2)" "unprognostic (2.17e-1)" "unprognostic (9.64e-2)" 1.2 11.1 14.5 0.9 10.8 0.9 1.6 2.6 32.7 0.9 2.1 5.9 0.0 0.9 1.0 0.8 0.9 0.8 1.0 1.0 10.3 13.8 1.0 2.3 1.1 0.8 13.7 5.6 0.8 0.8 0.7 1.9 0.8 26.7 4.5 1.7 0.0 1.0 0.9 0.8 0.9 1.1 1.2 30.0 0.9 0.9 1.6 14.5 0.0 0.8 0.9 0.8 1.6 0.3 0.5 0.4 1.9 0.3 0.3 0.3 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 14.3 7.1 0.0 0.0 0.0 0.0 0.0 2.5 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.6 0.3 0.0 0.2 0.2 0.0 1.5 0.1 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.1 1.5 0.3 0.4 0.2 0.1 0.2 0.2 0.1 0.3 0.1 0.5 0.3 0.2 1.9 0.3 0.2 0.4 0.1 0.0 14.5 10.8 2.6 9.3 10.3 13.8 13.7 5.6 26.7 14.5 MC3R MC3 ENSG00000124089 "Melanocortin 3 receptor" P41968 20 56248732-56249815 "G-protein coupled receptors, Predicted membrane proteins" "Biological rhythms" "G-protein coupled receptor, Receptor, Transducer" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "brain: 6.4" "Cell line enriched" "Detected in single" 24 "hTERT-HME1: 2.3" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Group enriched" "Detected in some" 5 "basal ganglia: 4.8;hypothalamus: 3.3;thalamus: 2.6" HPA074739 Uncertain "HPA074739: " 0.0 0.4 0.1 0.0 0.3 0.0 0.1 0.0 0.6 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 6.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 NPVF "C7orf9, RFRP" ENSG00000105954 "Neuropeptide VF precursor" Q9HCQ7 7 25224570-25228486 "Predicted secreted proteins" Neuropeptide "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 30 "brain: 9.5;lymphoid tissue: 2.9;retina: 7.0" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in single" 95 "hypothalamus: 9.5" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in single" 17 "hypothalamus: 7.2" "Region enriched" "Detected in some" 4 "hypothalamus: 3.8" HPA041733 Enhanced "Secreted in other tissues" "HPA041733: AB_10794524" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 9.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 2.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.5 0.0 0.0 0.0 0.0 OTP ENSG00000171540 "Orthopedia homeobox" Q5XKR4 5 77628712-77639688 "Predicted intracellular proteins, Transcription factors" "Differentiation, Neurogenesis, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 10 "brain: 16.2" "Cell line enhanced" "Detected in some" "HDLM-2: 3.2;SCLC-21H: 1.5;THP-1: 1.5" "Cancer enriched" "Detected in single" 6 "glioma: 1.2" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in some" 7 "hypothalamus: 23.4" "Region enhanced" "Detected in some" "hypothalamus: 24.0" HPA059342 Enhanced Supported "HPA059342: " "unprognostic (1.00e-1)" "unprognostic (2.40e-2)" "unprognostic (6.25e-2)" "unprognostic (8.06e-3)" "unprognostic (1.16e-1)" "unprognostic (7.77e-2)" "unprognostic (7.77e-2)" "unprognostic (2.39e-2)" "unprognostic (9.66e-2)" "unprognostic (4.64e-2)" "unprognostic (7.76e-14)" "unprognostic (3.38e-2)" "unprognostic (1.84e-1)" "unprognostic (9.49e-3)" 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 16.2 0.0 0.0 1.5 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.8 0.1 0.3 0.1 0.0 0.2 0.0 0.0 0.0 0.0 1.5 0.0 0.3 0.0 0.0 0.1 1.5 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 OXT "OT, OT-NPI, OXT-NPI" ENSG00000101405 "Oxytocin/neurophysin I prepropeptide" P01178 20 3071620-3072517 "Plasma proteins, Predicted secreted proteins" Hormone "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 10 "brain: 232.0" "Group enriched" "Detected in some" 4 "CACO-2: 5.1;HL-60: 1.3;HMC-1: 3.7;PC-3: 2.6" "Cancer enriched" "Detected in some" 5 "testis cancer: 12.1" "Region enriched" "Detected in some" 59 "hypothalamus: 232.0" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Region enriched" "Detected in some" 5 "hypothalamus: 210.0" "Group enriched" "Detected in some" 878 "basal ganglia: 840.1;hypothalamus: 2453.1" HPA071892 Supported Supported "Secreted to blood" 1501000 "HPA071892: " "unprognostic (7.45e-3)" "unprognostic (1.99e-2)" "unprognostic (2.66e-2)" "unprognostic (2.28e-1)" "unprognostic (2.62e-1)" "unprognostic (3.82e-2)" "unprognostic (8.22e-2)" "unprognostic (8.36e-2)" "unprognostic (6.02e-2)" "unprognostic (3.05e-2)" "unprognostic (6.65e-2)" "unprognostic (6.18e-1)" "unprognostic (3.81e-1)" "unprognostic (3.36e-2)" "unprognostic (1.95e-1)" "unprognostic (1.81e-1)" "unprognostic (1.10e-1)" 5.0 0.2 0.0 0.1 3.9 0.2 0.2 0.0 0.3 0.1 0.0 0.4 0.0 2.6 0.0 3.8 0.0 0.0 0.0 0.0 0.1 232.0 1.6 24.0 0.2 0.2 0.0 0.0 0.2 0.0 0.0 1.8 0.6 0.2 0.2 0.0 0.0 0.4 0.2 0.2 0.2 2.4 0.0 0.0 0.2 0.2 1.5 0.0 0.2 0.0 0.0 0.0 0.0 0.0 3.7 1.5 6.3 0.4 0.4 3.6 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.5 0.0 0.0 0.0 5.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 3.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.3 6.3 0.8 0.4 1.0 3.7 1.7 1.1 0.9 3.6 3.2 3.6 1.1 0.4 0.0 1.5 2.4 0.9 0.0 3.9 0.0 0.3 0.1 232.0 0.0 0.0 0.2 0.0 PABPC1L2A RBM32A ENSG00000186288 "Poly(A) binding protein cytoplasmic 1 like 2A" Q5JQF8 X 73077276-73079512 "Predicted intracellular proteins" RNA-binding "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 9.6;prostate: 5.2" "Cell line enhanced" "Detected in some" "HeLa: 8.9;NTERA-2: 3.3;SK-MEL-30: 1.8" "Cancer enriched" "Detected in single" 15 "prostate cancer: 1.8" "Not detected" "Not detected" "Not detected" "Not detected" HPA041573 Approved "HPA041573: " "unprognostic (4.30e-2)" "unprognostic (2.19e-1)" "unprognostic (3.22e-1)" 0.1 3.5 3.3 0.2 5.0 0.0 0.1 7.1 9.6 0.1 0.2 0.4 0.1 1.4 0.0 0.2 0.2 0.0 3.5 9.2 0.2 0.1 0.1 0.0 2.9 0.4 0.1 0.0 1.2 0.0 5.2 0.1 0.8 0.6 0.1 0.1 0.2 0.0 2.4 0.7 0.1 3.2 0.3 0.1 0.2 0.0 0.2 0.1 0.7 0.2 0.8 0.1 0.3 0.0 1.3 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.5 0.1 0.1 0.9 0.1 0.0 0.0 0.0 0.0 8.9 0.4 0.0 0.1 0.3 0.0 0.0 0.1 0.2 0.0 0.0 0.2 0.0 0.1 0.0 0.0 3.3 0.0 0.0 0.2 0.0 0.1 0.0 0.0 1.0 0.4 0.1 1.8 0.0 0.0 0.1 0.1 1.1 0.0 0.1 0.0 0.0 0.0 0.1 0.2 0.7 0.3 0.1 0.5 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.1 0.7 0.8 0.2 0.1 0.0 0.3 PABPC1L2B RBM32B ENSG00000184388 "Poly(A) binding protein cytoplasmic 1 like 2B" Q5JQF8 X 73003517-73005713 "Predicted intracellular proteins" RNA-binding "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 6 "brain: 12.2;prostate: 6.6" "Group enriched" "Detected in some" 30 "HAP1: 2.7;NTERA-2: 5.6;U-2 OS: 1.8" "Cancer enriched" "Detected in single" 23 "prostate cancer: 2.5" "Not detected" "Not detected" "Not detected" "Not detected" HPA041573 Approved "HPA041573: " "unprognostic (1.73e-1)" "unprognostic (2.26e-1)" "unprognostic (3.31e-1)" 0.1 1.6 3.3 0.1 4.9 0.1 0.1 6.4 12.2 0.1 0.1 0.4 0.1 0.5 0.1 0.1 0.1 0.1 3.5 10.2 0.1 0.1 0.1 0.1 3.3 0.1 0.1 0.1 1.0 0.1 6.6 0.1 0.8 0.5 0.1 0.1 0.1 0.1 2.1 0.2 0.1 1.5 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 PCSK2 "NEC2, PC2, SPC2" ENSG00000125851 "Proprotein convertase subtilisin/kexin type 2" P16519 20 17226107-17484578 "Enzymes, Predicted intracellular proteins, Predicted secreted proteins" "Hydrolase, Protease, Serine protease" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 35.0;thyroid gland: 79.5" "Group enriched" "Detected in some" 5 "AF22: 35.8;SCLC-21H: 9.4" "Group enriched" "Detected in many" 6 "pancreatic cancer: 14.6;thyroid cancer: 65.1" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 22 "basophil: 2.2" "Lineage enriched" "Detected in single" 22 "granulocytes: 2.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA049627 Approved Approved Vesicles "Secreted in other tissues" Vesicles "HPA049627: " "unprognostic (2.03e-3)" "unprognostic (1.61e-1)" "unprognostic (3.13e-1)" "unprognostic (2.18e-1)" "unprognostic (2.13e-1)" "unprognostic (6.84e-2)" "unprognostic (3.07e-3)" "unprognostic (4.31e-1)" "unprognostic (5.88e-2)" "unprognostic (2.50e-3)" "unprognostic (2.14e-1)" "unprognostic (7.26e-5)" "unprognostic (2.29e-1)" "unprognostic (1.57e-1)" "unprognostic (2.35e-1)" "unprognostic (1.14e-1)" 1.6 35.0 16.3 1.7 20.5 1.3 1.3 7.7 27.8 2.9 4.2 1.6 0.0 6.2 0.9 1.2 2.1 2.0 1.4 3.1 18.0 11.1 1.1 1.0 2.2 0.8 4.1 16.2 11.6 23.7 0.9 1.7 1.5 9.0 1.3 2.8 16.6 2.7 2.3 1.0 16.6 3.3 1.3 5.4 0.9 11.9 4.7 3.8 0.0 79.5 0.0 0.9 1.9 1.8 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 35.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 4.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 9.4 0.1 0.0 0.0 1.5 0.0 0.0 0.0 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 16.3 20.5 7.7 27.8 18.0 11.1 4.1 16.2 9.0 3.8 PMCH MCH ENSG00000183395 "Pro-melanin concentrating hormone" P20382 12 102196459-102197845 "Predicted secreted proteins" "Differentiation, Spermatogenesis" "Developmental protein, Hormone, Neuropeptide" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 11 "brain: 124.8" "Cell line enriched" "Detected in some" 8 "HDLM-2: 30.6" "Cancer enhanced" "Detected in single" "endometrial cancer: 0.8" "Region enriched" "Detected in some" 27 "hypothalamus: 124.8" "Cell type enriched" "Detected in some" 8 "T-reg: 11.3" "Lineage enriched" "Detected in single" 81 "T-cells: 11.3" "Group enriched" "Detected in some" 131 "hypothalamus: 737.6;thalamus: 373.6" "Region enriched" "Detected in single" 30 "hypothalamus: 98.6" "HPA046055, HPA061884" Enhanced Supported "Secreted to blood" 274240 "HPA046055: AB_2679517, HPA061884: AB_2684632" "unprognostic (3.23e-3)" "unprognostic (8.04e-2)" "unprognostic (3.96e-4)" "unprognostic (2.09e-2)" "unprognostic (1.75e-1)" "unprognostic (7.73e-2)" "unprognostic (4.31e-3)" "unprognostic (1.43e-2)" "unprognostic (3.18e-3)" "unprognostic (4.51e-2)" "unprognostic (1.21e-1)" "unprognostic (2.16e-6)" "unprognostic (1.17e-2)" "unprognostic (1.93e-1)" "unprognostic (5.10e-2)" "unprognostic (3.53e-2)" 0.1 0.0 0.3 2.1 2.0 2.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.5 1.1 1.0 0.0 0.2 0.6 0.8 124.8 0.1 0.1 0.2 6.4 0.4 0.1 0.1 0.1 0.0 1.4 0.2 4.5 0.2 0.0 0.1 0.2 0.1 0.1 0.9 0.1 0.1 0.9 1.1 2.0 0.2 0.7 1.0 0.1 0.1 1.7 0.2 0.1 0.0 0.0 0.0 0.0 0.1 11.3 0.0 0.3 0.1 0.3 0.3 0.0 0.0 0.6 0.4 0.0 0.0 0.0 0.0 0.2 0.2 0.2 0.0 0.2 0.0 0.0 0.0 30.6 0.1 0.5 0.6 0.3 0.0 1.0 0.4 0.0 0.0 0.0 0.0 3.7 0.7 0.1 0.0 0.0 0.6 1.0 0.5 1.2 0.3 0.6 1.2 0.0 0.2 0.3 0.4 0.4 0.6 0.1 0.2 0.1 0.4 0.4 0.4 0.1 0.5 0.1 0.5 0.4 0.4 0.8 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 11.3 0.0 0.3 2.0 0.1 0.1 0.8 124.8 0.4 0.1 4.5 0.7 PPP1R17 "C7orf16, GSBS" ENSG00000106341 "Protein phosphatase 1 regulatory subunit 17" O96001 7 31686715-31708455 "Predicted intracellular proteins" "Protein phosphatase inhibitor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 7 "adrenal gland: 10.5;blood: 24.5;brain: 29.7" "Group enriched" "Detected in some" 197 "NTERA-2: 15.3;SCLC-21H: 46.6" "Cancer enhanced" "Detected in single" "testis cancer: 0.5" "Group enriched" "Detected in many" 6 "cerebellum: 29.7;hypothalamus: 8.5" "Cell type enriched" "Detected in some" 4 "non-classical monocyte: 24.5" "Lineage enriched" "Detected in many" 19 "monocytes: 24.5" "Region enriched" "Detected in some" 32 "cerebellum: 483.2" "Region enriched" "Detected in many" 4 "cerebellum: 339.5" "HPA047819, HPA073123" Enhanced "HPA047819: , HPA073123: " "unprognostic (1.50e-1)" "unprognostic (1.33e-1)" "unprognostic (6.56e-2)" "unprognostic (5.55e-2)" "unprognostic (2.33e-1)" 0.6 10.5 0.9 0.6 1.3 0.8 0.1 29.7 4.6 0.1 0.1 1.7 0.0 0.1 0.8 0.3 0.1 0.1 0.1 0.4 0.6 8.5 0.1 0.2 1.1 0.1 1.1 0.9 0.1 0.1 0.1 2.9 0.1 2.6 0.3 0.1 0.3 0.4 0.1 0.1 0.1 0.1 0.4 1.0 0.3 0.3 1.7 3.0 0.0 0.1 0.0 0.2 0.1 0.0 0.1 1.2 0.0 24.5 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.3 0.0 0.0 0.0 0.0 0.0 0.0 46.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 5.8 0.0 0.0 0.0 0.0 1.2 0.1 0.0 0.0 0.0 0.0 24.5 0.0 0.0 0.4 0.9 1.3 29.7 3.3 0.6 8.5 1.1 0.9 2.6 3.0 PTPRN "IA-2, ICA512" ENSG00000054356 "Protein tyrosine phosphatase, receptor type N" Q16849 2 219289623-219309648 "Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Transcription, Transcription regulation" Receptor "Diabetes mellitus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 89.6;pancreas: 28.9;pituitary gland: 43.4" "Group enriched" "Detected in some" 8 "U-2 OS: 19.8;U-87 MG: 73.7" "Group enriched" "Detected in some" 12 "glioma: 5.3;pancreatic cancer: 18.4" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA007152, HPA007179" Enhanced Approved "Endoplasmic reticulum" "Endoplasmic reticulum" "HPA007152: , HPA007179: AB_1079714" "unprognostic (1.43e-1)" "unprognostic (1.33e-4)" "unprognostic (2.91e-3)" "unprognostic (5.83e-3)" "prognostic unfavourable (1.45e-7)" "unprognostic (3.64e-2)" "unprognostic (1.24e-4)" "unprognostic (1.58e-3)" "unprognostic (1.02e-1)" "unprognostic (6.20e-4)" "unprognostic (1.44e-2)" "unprognostic (1.54e-1)" "unprognostic (2.28e-10)" "unprognostic (1.43e-2)" "unprognostic (2.49e-1)" "unprognostic (1.10e-2)" "unprognostic (8.61e-2)" 1.7 22.3 19.3 4.7 35.7 1.7 1.3 17.3 89.6 1.2 2.4 2.5 0.0 2.5 1.5 1.2 1.5 1.3 1.5 1.4 21.6 40.1 1.5 1.2 1.4 1.3 14.4 19.8 1.3 28.9 1.2 43.4 1.4 22.0 1.4 1.9 3.1 1.2 1.3 1.2 2.0 2.5 2.4 3.5 1.3 6.0 1.4 2.1 0.0 1.5 0.0 1.2 2.7 0.0 0.1 0.3 0.2 0.0 0.0 0.6 3.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.2 0.0 0.0 0.0 0.0 0.3 1.3 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.5 0.0 0.1 2.5 0.0 6.1 0.0 0.0 0.1 0.1 0.4 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 4.8 3.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 19.8 0.0 0.0 0.0 0.0 0.2 73.7 0.0 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.1 0.3 0.1 0.0 0.4 0.2 0.0 0.0 0.0 0.6 3.7 19.3 35.7 17.3 54.0 21.6 40.1 14.4 19.8 22.0 2.1 QRFPR GPR103 ENSG00000186867 "Pyroglutamylated RFamide peptide receptor" Q96P65 4 121329312-121381059 "G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in some" "brain: 6.9;heart muscle: 4.6" "Cell line enhanced" "Detected in some" "HL-60: 5.2;hTERT-HME1: 7.1;RPTEC TERT1: 4.5;SCLC-21H: 2.9;U-2 OS: 7.7;WM-115: 4.3" "Cancer enriched" "Detected in some" 6 "renal cancer: 5.8" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "HPA014300, HPA050236" Approved "HPA014300: AB_1849251, HPA050236: " "unprognostic (1.24e-2)" "unprognostic (2.30e-1)" "unprognostic (1.93e-2)" "unprognostic (3.21e-1)" "unprognostic (2.77e-1)" "unprognostic (3.21e-4)" "unprognostic (2.71e-1)" "unprognostic (5.77e-3)" "unprognostic (5.37e-2)" "unprognostic (6.33e-2)" "unprognostic (2.12e-1)" "prognostic favourable (3.09e-4)" "unprognostic (3.09e-1)" "unprognostic (2.57e-1)" "unprognostic (1.61e-1)" 1.6 1.2 0.7 0.3 1.9 0.0 0.5 0.1 2.0 0.3 0.2 0.3 0.0 0.0 0.2 1.1 0.8 0.1 1.1 4.6 1.3 6.9 3.2 0.2 0.1 0.0 0.8 0.8 0.4 0.0 1.0 0.8 0.2 4.9 0.6 0.1 3.3 0.0 2.3 0.1 0.0 0.4 0.2 2.6 0.0 1.3 0.7 0.0 0.0 1.6 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 5.2 0.0 0.1 0.0 0.0 7.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.6 0.0 0.0 0.0 0.0 4.5 0.0 2.9 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 7.7 0.0 0.0 0.1 1.8 0.0 0.0 0.0 4.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 1.9 0.1 2.0 1.3 6.9 0.8 0.8 4.9 0.0 RTP5 "C2orf85, CXXC11, FLJ33590, Z3CXXC5" ENSG00000188011 "Receptor transporter protein 5 (putative)" Q14D33 2 241869600-241873823 "Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 18 "brain: 44.8" "Group enriched" "Detected in some" 29 "MOLT-4: 3.6;SCLC-21H: 7.2" "Cancer enriched" "Detected in single" 10 "glioma: 1.7" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" HPA050902 Enhanced "HPA050902: " "unprognostic (3.26e-2)" "unprognostic (5.38e-4)" "unprognostic (2.43e-2)" "unprognostic (1.15e-1)" "unprognostic (3.01e-1)" "unprognostic (9.40e-4)" "unprognostic (8.68e-3)" "unprognostic (2.04e-1)" "unprognostic (6.34e-4)" "unprognostic (3.30e-1)" "unprognostic (9.01e-3)" "unprognostic (3.91e-1)" "unprognostic (9.08e-8)" "unprognostic (1.81e-1)" "unprognostic (1.77e-1)" "unprognostic (2.68e-2)" "unprognostic (3.72e-2)" 0.8 0.8 27.9 1.1 44.8 1.9 0.7 0.2 13.5 0.7 0.7 2.1 0.0 0.9 0.7 0.7 0.7 0.7 0.8 0.8 32.9 24.9 0.7 0.7 0.8 2.4 3.1 4.8 0.7 0.9 0.7 0.0 0.7 7.3 0.7 0.7 0.0 0.9 0.7 0.7 0.7 0.7 0.7 2.1 1.1 0.8 0.7 1.5 0.0 0.7 0.0 1.1 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 7.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 27.9 44.8 0.2 12.7 32.9 24.9 3.1 4.8 7.3 1.5 SCG2 "CHGC, SgII, SN" ENSG00000171951 "Secretogranin II" P13521 2 223596940-223602503 "Plasma proteins, Predicted secreted proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "adrenal gland: 133.0;brain: 94.1;pituitary gland: 76.5" "Cell line enhanced" "Detected in some" "ASC TERT1: 26.2;HSkMC: 22.4;SCLC-21H: 22.8;SH-SY5Y: 9.9;WM-115: 16.7" "Group enriched" "Detected in many" 8 "glioma: 70.0;pancreatic cancer: 52.9" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA011893, HPA075062" Enhanced Supported Approved "Golgi apparatus,Vesicles" "Secreted to blood" 54000 "Golgi apparatus" Vesicles "HPA011893: AB_1856656, HPA075062: AB_2732277" "unprognostic (2.93e-2)" "unprognostic (1.44e-2)" "unprognostic (1.23e-3)" "unprognostic (6.82e-4)" "unprognostic (2.51e-2)" "unprognostic (1.13e-2)" "unprognostic (2.77e-3)" "unprognostic (6.73e-2)" "unprognostic (1.08e-1)" "unprognostic (4.69e-2)" "prognostic favourable (5.58e-4)" "unprognostic (1.34e-1)" "prognostic unfavourable (7.01e-10)" "unprognostic (2.47e-3)" "unprognostic (4.02e-1)" "unprognostic (1.57e-2)" "unprognostic (1.90e-3)" 3.5 133.0 13.3 11.0 94.1 0.9 0.9 5.6 55.9 1.4 5.4 5.8 0.0 17.3 2.1 0.9 1.0 0.8 2.2 1.4 10.5 79.4 1.0 0.8 1.9 0.9 21.7 11.0 1.3 10.7 1.1 76.5 1.1 57.7 2.1 5.5 1.5 0.9 1.3 0.8 1.0 8.0 5.2 10.3 0.8 8.0 0.9 5.0 0.0 3.1 0.0 0.8 1.1 0.2 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 1.4 4.9 4.1 1.1 26.2 0.1 0.2 0.9 1.9 4.9 0.2 0.4 0.0 0.4 0.3 0.1 0.1 0.0 2.5 0.0 0.2 0.0 0.3 0.0 0.3 0.3 2.2 22.4 0.1 2.7 0.9 0.0 0.1 0.2 2.4 0.1 0.0 0.1 3.5 0.0 0.0 0.1 0.0 0.3 0.0 22.8 9.9 0.0 0.2 1.1 0.0 0.0 0.0 2.6 1.0 0.1 1.7 0.0 0.0 0.1 0.7 0.0 16.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 13.3 94.1 5.6 23.0 10.5 79.4 21.7 11.0 57.7 5.0 SST SMST ENSG00000157005 Somatostatin P61278 3 187668906-187670399 "Cancer-related genes, Plasma proteins, Predicted secreted proteins" Hormone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "brain: 102.8;intestine: 105.2;pancreas: 105.6;stomach 1: 90.4" "Cell line enhanced" "Detected in some" "EFO-21: 15.2;U-2 OS: 28.3;U-251 MG: 4.7;U-698: 5.9" "Group enriched" "Detected in many" 7 "ovarian cancer: 249.9;pancreatic cancer: 1039.3" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB000075, HPA019472, CAB034105" Enhanced Supported "Secreted to blood" "CAB000075: AB_2688022, CAB034105: AB_2271061, HPA019472: AB_1857360" "unprognostic (2.44e-1)" "unprognostic (2.05e-1)" "prognostic unfavourable (1.93e-5)" "unprognostic (5.12e-3)" "unprognostic (1.54e-2)" "unprognostic (4.69e-1)" "unprognostic (3.31e-2)" "unprognostic (8.16e-3)" "unprognostic (1.63e-1)" "unprognostic (1.07e-3)" "unprognostic (8.47e-2)" "unprognostic (4.19e-1)" "unprognostic (3.27e-1)" "unprognostic (1.45e-1)" 2.0 13.0 28.6 1.9 53.8 1.7 0.7 0.1 47.9 0.7 45.1 1.8 21.9 105.2 0.9 0.7 1.1 0.7 1.0 0.9 17.5 102.8 2.5 0.7 0.7 1.0 6.2 15.4 0.8 105.6 0.7 1.5 0.7 16.1 1.5 7.4 0.4 0.7 7.5 0.7 3.1 36.1 1.4 18.4 0.7 90.4 0.7 8.6 0.0 0.9 0.0 0.7 4.6 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.2 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 28.3 0.3 4.7 0.0 1.6 5.9 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 28.6 53.8 0.1 47.9 17.5 102.8 6.2 15.4 16.1 8.6 TPPP3 "CGI-38, p20, p25gamma" ENSG00000159713 "Tubulin polymerization promoting protein family member 3" Q9BW30 16 67389809-67393535 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "fallopian tube: 211.3" "Cell line enhanced" "Detected in some" "A549: 29.6;RH-30: 15.8;SCLC-21H: 24.4;SH-SY5Y: 10.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "non-classical monocyte: 26.2" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA047629, HPA061691" Enhanced Approved "Nucleoli fibrillar center" 29000 "Nucleoli fibrillar center" "HPA047629: , HPA061691: " "unprognostic (1.63e-1)" "unprognostic (6.62e-3)" "unprognostic (1.35e-1)" "unprognostic (7.28e-3)" "unprognostic (4.48e-3)" "unprognostic (1.59e-3)" "unprognostic (9.22e-2)" "unprognostic (3.23e-1)" "unprognostic (1.46e-2)" "unprognostic (2.93e-2)" "unprognostic (1.02e-3)" "unprognostic (7.98e-2)" "prognostic unfavourable (8.84e-4)" "unprognostic (3.51e-2)" "unprognostic (9.44e-2)" "unprognostic (9.46e-2)" "unprognostic (1.86e-3)" 9.6 7.6 30.5 2.9 20.7 1.0 21.9 3.7 25.0 12.8 11.9 70.3 2.0 6.4 7.2 15.1 24.8 211.3 6.0 11.3 36.4 41.9 6.1 1.9 36.3 1.7 26.4 22.1 14.1 6.5 2.2 5.8 70.6 24.5 3.4 4.3 2.2 5.2 4.2 14.4 28.1 9.8 10.0 40.6 3.8 11.3 2.6 24.4 0.1 3.5 37.6 6.1 7.4 5.5 0.0 14.1 5.2 26.2 0.0 0.1 3.6 0.2 29.6 0.3 0.2 0.2 4.9 0.1 0.8 0.2 0.2 0.4 1.9 6.0 0.0 0.4 0.4 5.6 4.6 0.0 0.0 0.0 1.7 0.0 0.8 0.8 0.0 0.0 0.0 1.2 0.1 1.8 0.0 0.3 0.0 0.0 2.7 0.1 0.0 0.1 1.0 0.0 0.0 15.8 0.1 0.0 0.0 24.4 10.5 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.3 0.3 0.0 0.0 0.0 0.0 1.5 0.0 0.4 0.0 10.9 5.2 0.0 15.4 0.1 0.0 0.0 0.0 14.1 0.0 0.0 0.0 2.6 0.0 26.2 0.1 0.0 3.6 30.5 20.7 3.7 23.8 36.4 41.9 26.4 22.1 24.5 24.4 TRH ENSG00000170893 "Thyrotropin releasing hormone" P20396 3 129974305-129977938 "Predicted secreted proteins" Hormone "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 33.9;cervix, uterine: 23.6;endometrium 1: 17.5" "Cell line enhanced" "Detected in some" "REH: 3.1;T-47d: 2.9" "Cancer enhanced" "Detected in some" "breast cancer: 13.3;endometrial cancer: 10.2" "Group enriched" "Detected in many" 14 "hypothalamus: 33.9;pons and medulla: 33.8" "Group enriched" "Detected in some" 11 "intermediate monocyte: 1.1;non-classical monocyte: 1.0" "Lineage enriched" "Detected in single" 12 "monocytes: 1.1" "Group enriched" "Detected in many" 5 "hypothalamus: 204.6;olfactory region: 182.2" "Low region specificity" "Detected in many" HPA035596 Enhanced "Secreted in other tissues" "HPA035596: " "unprognostic (1.22e-1)" "unprognostic (8.94e-2)" "unprognostic (5.82e-3)" "unprognostic (5.24e-2)" "unprognostic (2.82e-1)" "unprognostic (1.11e-1)" "unprognostic (1.84e-1)" "unprognostic (4.44e-2)" "unprognostic (3.86e-2)" "unprognostic (1.50e-1)" "unprognostic (1.71e-2)" "unprognostic (2.85e-1)" "unprognostic (1.95e-1)" "unprognostic (2.57e-2)" "unprognostic (2.82e-2)" 0.3 0.1 0.4 0.2 2.4 2.8 0.9 0.3 1.7 23.6 0.1 0.1 0.6 0.2 17.5 0.1 0.1 2.3 0.1 0.5 2.0 33.9 0.1 0.1 0.6 0.1 0.4 0.8 3.2 0.1 0.1 0.1 0.3 33.8 0.1 0.1 6.3 1.0 0.2 0.2 0.5 0.1 0.4 3.6 0.1 0.1 0.8 0.0 0.8 0.1 0.0 0.1 0.1 0.3 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.2 0.0 0.9 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.4 0.2 0.0 3.1 0.0 0.0 0.0 0.0 0.5 0.1 0.3 0.0 0.0 2.9 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.4 2.4 0.3 1.7 2.0 33.9 0.4 0.8 33.8 0.0 VGF "SCG7, SgVII" ENSG00000128564 "VGF nerve growth factor inducible" O15240 7 101162509-101165593 "Plasma proteins, Predicted secreted proteins" "Antibiotic, Antimicrobial, Growth factor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 7 "brain: 59.4;pituitary gland: 30.4" "Cell line enhanced" "Detected in some" "SH-SY5Y: 35.9;SK-MEL-30: 96.8;U-2 OS: 17.6;WM-115: 29.0" "Cancer enriched" "Detected in many" 6 "melanoma: 236.3" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA055177, HPA072505" Enhanced Supported "Golgi apparatus,Vesicles" "Secreted to blood" 1273770 2800000 "Golgi apparatus, Vesicles" "HPA055177: AB_2682728, HPA072505: AB_2686528" "unprognostic (3.04e-2)" "unprognostic (3.45e-1)" "unprognostic (3.19e-3)" "prognostic unfavourable (4.25e-4)" "prognostic unfavourable (3.31e-4)" "unprognostic (1.51e-2)" "unprognostic (2.86e-2)" "unprognostic (1.66e-3)" "unprognostic (2.25e-2)" "unprognostic (8.77e-2)" "unprognostic (3.84e-3)" "unprognostic (3.70e-3)" "unprognostic (9.82e-3)" "unprognostic (3.79e-1)" "unprognostic (7.23e-2)" "unprognostic (4.36e-3)" "unprognostic (2.21e-1)" 3.8 3.1 10.9 2.3 25.2 1.3 1.1 1.3 59.4 1.1 1.5 1.3 0.0 1.3 2.2 1.1 1.1 1.1 1.2 1.2 12.2 51.0 1.4 1.1 1.1 1.1 3.9 22.8 1.1 6.2 1.1 30.4 1.2 41.2 1.2 1.2 0.5 1.1 1.1 1.1 1.4 1.3 1.5 6.6 1.2 3.6 1.4 0.5 0.0 1.2 0.0 1.2 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.2 0.2 1.9 0.0 0.0 2.1 0.1 0.0 0.0 0.0 0.4 0.1 0.0 0.6 0.0 0.2 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.9 0.0 0.0 0.0 0.1 0.0 0.7 0.4 0.0 4.6 0.0 0.4 3.6 0.4 0.1 0.0 0.0 0.0 0.0 2.9 35.9 0.0 0.1 96.8 0.0 0.0 0.0 0.0 17.6 0.0 0.4 0.0 0.1 0.9 2.8 0.0 29.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.9 25.2 1.3 59.4 12.2 51.0 3.9 22.8 41.2 0.5